Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown125%
terminated250%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Study of SCB01A in Patient With Head and Neck Cancer

NCT02488629
terminatedphase_2

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer

NCT03020823
unknown

Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

NCT01151930
completedphase_1

A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy

NCT01159522

Clinical Trials (4)

Showing 4 of 4 trials
NCT02488629Phase 2

Study of SCB01A in Patient With Head and Neck Cancer

Terminated
NCT03020823Phase 2

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer

Terminated
NCT01151930

Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

Unknown
NCT01159522Phase 1

A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4